Editorial board member Nicola A Hanania (Baylor College of Medicine, TX, US) considers the role of biologics in the management of asthma and chronic obstructive pulmonary disease (COPD).
1. What have been the most promising advances in molecular phenotyping of asthma and chronic obstructive pulmonary disease (COPD)? (0:12)
2. How are selective blood biomarkers being used to inform therapeutic decisions in COPD and asthma patients? (1:33)
3. What are the advantages and limitations of the new biologic therapies in severe asthma and COPD? (2:50)
4. What is the role of macrolides in the treatment paradigm of severe asthma and COPD? (5:14)
5. What do you see as the remaining unmet needs in this area? (6:47)
Speaker disclosure: Nicola A Hanania has received honoraria for serving on advisory boards or as a consultant for Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Novartis, and Sanofi/Regeneron. His institution has received research grant support on his behalf from Boehringer Ingelheim, AstraZeneca, Roche, and GlaxoSmithKline.
Filmed at the European Respiratory Society (ERS) International Congress 2018, Paris, France, September 2018.
Share this Video
Related Videos In COPD
Donald Mahler, CHEST 2021: Precision Medicine in COPD
We were delighted to speak with Prof. Donald Mahler (Geisel School of Medicine, Dartmouth, NH, USA) to explore his presentation ‘Precision Medicine in COPD’, which was presented at CHEST 2021, 17-20 October 2021. Questions What is the limitation of traditional approaches to the treatment of COPD? (0:26) What are the major challenges of moving to […]
Douglas Mapel, ATS 2021: The Rate of ED Visits in Patients with COPD in the IMPACT Trial
It was a pleasure to meet with Dr Douglas Mapel (Northern Arizona Pulmonary Associates – Critical Care, Flagstaff, AZ, US) to talk around his abstract on ‘Reduction in Emergency Department (ED) Visits in Patients with Chronic Obstructive Pulmonary Disease (COPD): Analysis of the IMPACT Trial.‘, which was presented at ATS 2021 International Conference, 14-19 May, […]
Brian Carlin, CHEST 2020 – New Thoughts in COPD
Brian Carlin (Pittsburgh Critical Care Associates, Pittsburgh, PA, US) talks to us about recent developments in the treatment of COPD and the impact COVID-19 has had on pulmonary rehabilitation services. Questions 1. What have been the most exciting recent developments in inhaled therapies for COPD? (0:20) 2. What factors should physicians consider before prescribing inhaled […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!